Half-year sales of €3.3 million, exceeding 2023 full-year sales 20 implants of the Aeson® artificial heart performed in the first half of 2024 17% cash-burn1 reduction compared to the first half of 2023 2024 anticipated annual sales of €8 to €12 […]
Author: Ken Dropiewski
Vektor Medical Unveils Groundbreaking Research on AI and Deep Learning Innovations in Ventricular Tachycardia Analysis
September 06, 2024 07:59 AM Eastern Daylight Time ATLANTA–(BUSINESS WIRE)–Vektor Medical, a leader in non-invasive, AI-powered arrhythmia analysis technology, will present findings today at HRX 2024. The two studies showcase how Vektor’s advanced technologies uniquely leverage AI and deep learning […]
New cardiology guidelines require use of ultrasound enhancing agent during stress echo for perfusion
CHICAGO–(BUSINESS WIRE)–New international cardiology guidelines require the use of an ultrasound enhancing agent during stress echocardiograms to assess myocardial perfusion in patients with ischemia, as well as left ventricular heart function, according to a British cardiologist who is a co-author […]
First-on-Podium Data from 21 Vascular and Venous Clinical Trials to Be Presented at The VEINS and VIVA 2024
PALM SPRINGS, Calif., Sept. 6, 2024 /PRNewswire/ — Leading physicians and researchers will present results from 21 clinical trials from Sunday, November 3, to Tuesday, November 5, at the annual VIVA and The VEINS conferences at Wynn Las Vegas. VIVA (Vascular InterVentional Advances) is a…
Medtronic EV ICD global pivotal trial final results demonstrate high ATP success and effective defibrillation: ESC Congress 2024
Benefits of transvenous implantable defibrillators, including anti-tachycardia pacing (ATP), in a single device implanted safely outside the vascular space: 77% ATP success rate, in line with transvenous ICDs Avoided shocks in nearly half of all ventricular tachycardia/ventricular fibrillation (VT/VF) episodes […]
Elutia Announces First Patient Implant of EluPro™, the World’s First Drug-Eluting BioEnvelope for Cardiac Pacemakers and Neurostimulators
SILVER SPRING, Md., Sept. 05, 2024 (GLOBE NEWSWIRE) — Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix products, today announced a landmark achievement with the first-ever patient implant of EluPro®, the world’s first antibiotic-eluting biologic envelope cleared by the U.S. Food and Drug Administration (FDA). The groundbreaking procedure was performed by John Catanzaro, MD, MBA, Chief, Division of Cardiology, Director, Cardiology Services, and Program Director of Clinical Cardiac Electrophysiology Fellowship at East Carolina University Health Medical Center in Greenville, North Carolina.
WhiteSwell Expands Leadership Team with Key Appointments
New vice president of clinical affairs and board of directors member will support advancement of eLym™ System therapy for acute decompensated heart failure GALWAY, Ireland — September 5, 2024 — WhiteSwell, a company pioneering a new paradigm in the treatment of acute decompensated heart […]
Society for Vascular Surgery Vascular Quality Initiative Launches Carotid Care Quality Champion Program
September 05, 2024 09:09 AM Eastern Daylight Time CHICAGO–(BUSINESS WIRE)–The Society for Vascular Surgery® Vascular Quality Initiative® (SVS VQI) clinical registry today announced the Carotid Care Quality Champion recognition program. The program honors healthcare organizations across the country dedicated to improving the safety […]
Medera Inc. to be Listed on NASDAQ Through a Merger Agreement with Keen Vision Acquisition Corporation
Medera is a clinical-stage biotechnology company focused on targeting difficult-to-treat cardiovascular diseases using a range of next-generation gene- and cell-based approaches in combination with bioengineered human mini-heart drug discovery and screening technology platforms…
Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration
NANJING, China, Sept. 5, 2024 /PRNewswire/ — On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation…
Recent
Popular
- No commented posts yet